Mangafodipir as an intracellular contrast agent in cardiac MRI

The project is interdisciplinary and involves different departments at Oslo University Hospital, Rikshospitalet, including the cardiac department, the clinic for radiology and nuclear medicine, and the intervention center.  Furthermore, it is a collaboration with IC Targets, a Norwegian company that holds the patent rights for the use of Mangafodipir for CMR applications, with funding from the Research Council of Norway. The overarching goal is to contribute to the development of a new tool in cardiac MRI, which can be implemented in clinical practice for the benefit of heart failure patients.